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A B S T R A C T
Herpes simplex virus 1 (HSV-1) is a nearly ubiquitous human pathogen, remaining dormant in its human
host the majority of the time. The interaction between HSV-1 and the immune system represents a
complicated balance of power that allows the virus to persist in the host for a lifetime. However,
disruptions in the immune system can activate the virus with the potential to cause devastating
infections in the central nervous system (CNS). We present a patient who suffered three consecutive
yearly HSV-1 CNS episodes (encephalitis, seizure, and retinitis), each within days of his inﬂuenza
vaccination. We highlight subtle immunologic defects in this patient that may have allowed unchecked
viral replication and resultant disease manifestations, as well as the potential role of inﬂuenza vaccine in
tipping this balance in favor of HSV-1.
ã 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Between 52% and 84% of the human adult population is latently
infected by HSV-1 [1]. The large double stranded DNA virus
maintains lifelong infection by establishing a predominantly latent
infection within the trigeminal ganglia that is punctuated by
recurrent episodes of productive replication, or reactivation, that
results in clinical disease and dissemination of virus either within
the host or to new hosts. Rare manifestations of HSV-1 reactivation
include Herpesvirus encephalitis (HSE) and acute retinal necrosis
(ARN).
We present a case of HSV-1 HSE followed by post-HSE
encephalitis or seizure and HSV-1 ARN in which HSV infection
or reactivation was temporally associated with administration of
inﬂuenza vaccination in three consecutive years.
Case presentation
A 47-year-old male with insulin-dependent diabetes mellitus,
hypertension and dyslipidemia presented to an outside hospital
in November of 2012 with acute fever, aphasia and dysnomia
as well as a several day history of weakness, malaise and
hiccups. He was tachycardic and laboratory evaluation revealed a* Corresponding author.
E-mail address: david_diloreto@urmc.rochester.edu (D.A. DiLoreto).
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2214-2509/ã 2016 The Authors. Published by Elsevier Ltd. This is an open access article unleukocytosis (12,400/mm3) without bandemia as well as
hyponatremia (129 meq/L), hypochloremia (93 meq/L) and hy-
perglycemia (270 mg/dL). He was admitted to the ICU for sepsis
and dehydration. His lumbar puncture revealed clear ﬂuid with
elevated WBC (7), RBC (271) and glucose (188), normal protein
and no organisms.
An MRI of his brain revealed edema of the left temporal lobe and
pre-insular cortices without enhancement. His EEG demonstrated
bilateral temporal lobe slowing without epileptiform changes,
prompting treatment with intravenous acyclovir for presumed
HSV encephalitis. His CSF PCR was positive for HSV-1 DNA at
100 copies/ml and negative for HSV-2.
An MRI, repeated two weeks later, showed enhancement of the
left temporal lobe and bilateral insular cortices (Fig. 1 top left and
top right). His anti-herpetic therapy was transitioned to foscarnet
6 g IV BID and his condition improved. He was discharged to a
rehabilitation facility after one month and experienced a good
recovery.
His medical history was notable for cold sores as a child as well
as an inﬂuenza vaccination ten days prior to this presentation
(Fluvarix, 2012–2013 formula, GlaxoSmithKline, London, England).
He tested negative for inﬂuenza A or B. His absolute lymphocyte
counts were consistently low throughout his hospitalization,
between 400 and 800/mm3 (normal range 1300–3600/mm3).
The patient presented eleven months later with aphasia and
dysnomia three days after receiving an inﬂuenza vaccination
(Agriﬂu, 2013–2014 formula, Novartis, Basel, Switzerland). He wasder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Herpes simplex encephalitis. MRI brain at one month (top left, top right) and one year (bottom left, bottom right) following the initial presentation. T1 with contrast
axial (top left) and coronal (top right) images taken one month after the initial presentation showing enhancement in the left temporal lobe and subinsular cortex as well as
signal abnormality in the right and left insular cortices. T2 without contrast axial (bottom left) and coronal (bottom right) images taken at one year when the patient
presented with transient recrudescence of his symptoms.
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lymphocyte count was again low at 1100/mm3. His symptoms
resolved within hours without anti-viral treatment and a non-
contrast MRI demonstrated only left temporal lobe encephaloma-
lacia (Fig. 1 bottom left and bottom right), which was felt to be
sequelae of his prior HSE. EEG demonstrated bilateral temporal
slowing without epileptiform discharges. This episode was
diagnosed as a temporal lobe seizure related to structural
compromise and he was started on prophylactic levetiracetam
(Keppra; LEV) at 500 mg BID.
One year later, he developed eye pain, tearing and loss of vision
in the left eye one day after receiving inﬂuenza vaccination
(Fluzone, 2014–2015 formula, Sanoﬁ Pasteur, Paris, France). On
presentation two days later, his vision was limited to hand motion
and he had a left afferent pupillary defect, conjunctival hyperemia,
optic nerve and retinal edema and scattered retinal hemorrhages.
He was referred to our retina service the following day, at which
time his vision had deteriorated to light perception only. His
fundus exam revealed mild vitritis, retinal whitening, vascular
sheathing and peripheral choroidal effusions (Fig. 2 left).
Fluorescein angiography demonstrated occlusive vasculitis
(Fig. 2 right).
An aqueous ﬂuid sample was sent for PCR and the patient was
empirically treated for viral retinitis (acute retinal necrosis) withintravitreal foscarnet (2.4 mg/0.1 ml), subtenon's triamcinolone
(40 mg) and oral valacyclovir (1000 mg BID). The aqueous ﬂuid PCR
was positive for HSV-1 (150,000 copies/mL) and negative for HSV-
2, VZV and CMV. Four days later, his visual acuity was still light
perception although improvement was noted in his retinitis and
vitritis. He was additionally treated with a 5-day course of oral
prednisone at 60 mg daily.
Over the ensuing weeks severe retinal atrophy progressed
with the development of several atrophic holes and the retina
became totally detached. The patient underwent a pars plana
vitrectomy, air-ﬂuid exchange, endolaser and silicone oil ﬁll. His
vision improved to hand motion in the temporal ﬁeld at one
year, however his retina remains ischemic with a chronic
inferotemporal detachment still under silicone oil tamponade.
His exam also shows pallor of the optic nerve and severe
vascular attenuation. He is being maintained on valacyclovir
(500 mg daily) for life and has been advised to avoid future
inﬂuenza vaccination.
Laboratory studies at this time again revealed decreased
total lymphocytes 1200/mm3 as well as CD4T cells at 461/mm3
(normal 496–2186/mm3), despite overall normal total leukocyte
counts. His immunglobulin subset levels were normal and
demonstrated good reactivity to inﬂuenza, tetanus and Varicella
zoster.
Fig. 2. Acute retinal necrosis. Fundus photograph (left) showing retinal whitening, vascular occlusion, numerous retinal hemorrhages and disc edema. Flourescein angiogram
(right) showing leaking and staining of the central retinal arterioles and venules and severe peripheral nonperfusion consistent with occlusive vasculitis.
L.M. Hassman, D.A. DiLoreto / IDCases 6 (2016) 47–51 49Discussion
Primary HSV infection
Upon initial oral mucocutaneous exposure, HSV-1 undergoes
robust replication resulting in production of millions of progeny
virions, which enter the distal axon terminals of peripheral
neurons. The viral particles follow retrograde axonal transport to
the nucleus where latent infection is established, usually in the
trigeminal ganglion.
In the trigeminal nuclei, the viral genome circularizes and
becomes coated with host cell protein complexes that inhibit viral
gene transcription. Cellular stress, including apoptosis, hypoxia or
loss of growth factor support, results in de-repression of viral
transcription. This leads to reactivation marked by a highly ordered
cascade of viral gene transcription culminating in viral DNA
replication, followed by assembly of progeny virions.
The newly synthesized virions undergo anterograde axonal
transport to the overlying skin and mucous membranes where
they are released to infect neighboring cells or other hosts. Indeed,
nearly 100% of infected, but asymptomatic, subjects intermittently
shed HSV-1 DNA from either saliva or tears [2].
Host defense and the maintenance of viral latency
Under normal conditions, viral replication and morbidity to the
host are limited by both pathogen and host factors, allowing the
virus to persist for the host’s lifetime. Numerous host defense
mechanisms are poised to limit HSV infection. Viral DNA, RNA and
proteins are detected by the host via pathogen recognition
receptors, such as the toll-like receptors (TLRs). Activation of
these receptors results in release of pro-inﬂammatory cytokines,
particularly type II interferons and IL-1b, which inhibit viral
replication, promote destruction of infected cells and recruit
phagocytes to clear infected cells.
Resident microglia and inﬁltrating CD8+ T cells provide
additional defense in the form of direct cellular toxicity and
anti-viral cytokines. Recurrent subclinical viral replication incites a
local inﬂammatory response that triggers immune surveillance of
infected trigeminal ganglia. This phenomenon, in conjunction with
viral regulatory elements, is critical for repressing clinically
apparent infection. Thus, clinical disease represents a tip in this
balance in favor of viral proliferation.CNS dissemination
Just as anterograde transport facilitates spread of virions from
the trigeminal ganglia to the skin and mucous membranes, it also
allows dissemination into the central nervous system (CNS), most
commonly to the frontal and temporal cortices. Post-mortem
histology and PCR performed on patients without clinically
apparent infection demonstrates HSV-1 in the trigeminal ganglia
of 60% of autopsy cases [3], a frequency that corroborates the
prevalence estimates of 50–80% [1]. Both latent and replicative
HSV-1 have been detected in the central nervous system of 30–55%
of clinically asymptomatic autopsy cases [4], suggesting an
alarmingly high rate of viral spread from the periphery to the
CNS. Indeed, HSV-1 transcripts were detected in the CNS of all
patients with HSV-1 positive trigeminal ganglia in a seven patient
autopsy case series [5].
Despite the frequency of asymptomatic CNS infection, herpes
encephalitis (HSE) is quite rare with prevalence estimates of 1/250-
500,000. It is a potentially devastating infection characterized by
necrotizing inﬂammation, predominantly in the temporal lobe.
Even with antiviral therapy, the mortality rate is between 14% and
19%, and the rate of neurologic morbidity is 40–60% [6]. Notably,
the viral load correlates with disease severity [7].
Post-HSE encephalitis occurs weeks to months after initial
presentation in up to 25% of surviving patients and is characterized
by progression or recrudescence of the original deﬁcits. In contrast
to the initial viral encephalitis, this syndrome is primarily
immune-mediated, characterized by enhancement of previous
brain lesions on MRI and CSF inﬂammation without detectable
virus. Accordingly, post-HSE encephalitis responds to immuno-
modulatory therapy but not to extension of antiviral therapy [8].
This inﬂammatory response may be the result of persistent
undetectable or abortive viral replication or a chronic immune
response triggered by the initial infection.
Acute retinal necrosis (ARN) is a rare and potentially devastat-
ing infection by HSV-1, HSV-2 or VZV characterized by rapidly
progressive retinal necrosis, optic neuritis, retinal vasculitis and
vitritis. The retinal necrosis is so severe that detachment ensues in
35–80% of patients [9]. It is caused by VZV about twice as
frequently as HSV-1 in adults, and more commonly by HSV-2 in
patients under 25 [9].
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There are numerous case reports of ARN following HSE [10]. In
one series of 52 patients with ARN, 13% of ARN were preceded by
HSE. Of those, ﬁve were caused by HSV-1 and two by VZV,
opposite to the etiologic trend for ARN without HSE, though the
signiﬁcance of this is unclear since the total number of cases was
small [9]. However, in a separate publication, the same authors
detected concordance between HSV strains in CSF during HSE and
ocular ﬂuid during ARN in two patients [11]. Taken together, these
data suggest that viral encephalitis may predispose patients to
ARN and that HSV-1 may pose more of a risk for post-HSE ARN
than VZV.
HSV may gain entry to the ocular environment via the
nasociliary branch of the trigeminal nerve, which supplies the
anterior segment of the eye, and probably transports the virions
that cause keratitis or iritis. Alternatively, HSV may traverse the
optic nerve after meningeal spread from the trigmeninal ganglion.
Optic disc edema is, in fact, a common feature of ARN and there
have been multiple cases of ARN that were preceded by optic
neuritis [12]. Notably, intracerebral inoculation of HSV-1 results in
retinitis in murine models [13].
Immune mechanisms for viral suppression
The ability of the host cell to sense and respond to HSV is highly
complex with receptors poised to detect each intermediate (viral
DNA, RNA and protein), and safeguarded with intrinsic regulatory
components that limit the extent of inﬂammation and prevent
tissue destruction and autoimmunity. One family of pathogen-
sensing receptors is the toll-like receptors (TLRs). TLR3 recognizes
double stranded RNA, TLR7 and TLR8 detect single stranded RNA
and TLR9 binds viral DNA. Many of the signal cascades induced by
TLR ligation converge to activate either interferon regulatory factor
3 (IRF3) or IRF7, both strong inducers of type I interferons (IFN).
Polymorphisms in the TLR3-IFN pathway have been implicated in
pediatric and adult herpetic encephalitis and may be quite
common among patients with HSE [14]. Notably, these defects
do not render the patients susceptible to mucocutaneous HSV-
1 infections, or to other viral infections, but speciﬁcally to herpetic
encephalitis.
While most TLRs are expressed in the CNS, there may be
differences in the relative expression levels that render TLR3, in
particular, more critical in the CNS. Teleologically, less redundancy
in this system may serve to prevent immune-mediated CNS tissue
destruction. TLR3 signals may also reduce immunopathology by
providing anti-viral speciﬁcity to the immune response. Alter-
ations in TLR3 signaling, therefore, may tip the immunologic
balance from controlled viral occupancy toward rampant infection
with uncontrolled CNS inﬂammation.
Additionally, speciﬁc immune modulating therapies may
render patients susceptible to HSE or meningitis in the absence
of mucocutaneous infection. The implicated medications include
the TNFa inhibitors [15], as well as drugs that reduce immunologic
surveillance by preventing leukocyte migration either out of the
lymph nodes, in the case of the sphingosine-1-phosphate receptor
antagonist Fingolimod [16], or into tissues, in the case of the
a4 integrin antagonist Natalizumab [17]. These reports are rare
among patients receiving these drugs, suggesting that patient-
speciﬁc factors are also important, yet they highlight critical
components of the CNS-speciﬁc immune response to herpesvirus
infections and suggest, again, that there is a reduced immunologic
redundancy in the CNS compared to the periphery.Inﬂuenza vaccination as a trigger for HSV reactivation
There are very rare reports of neurologic complications,
including encephalitis, following inﬂuenza vaccination, totaling
13 out of 38 million doses over 10 years in one Japanese study [18]
and, not surprisingly, the underlying pathology is unknown.
Proposed immunologic mechanisms include molecular mimicry,
whereby immunity to a vaccine peptide triggers a demyelinating
immune response against a similar host protein; and auto-
inﬂammation, for which vaccination triggers robust inﬂammation
that results in generalized tissue damage within the CNS. In
support of the latter theory, a recent murine study showed that
intranasal infection with a non-neurotropic inﬂuenza virus
resulted in reduced levels of neurotrophin in the brain and
activation of brain microglial cells [19]. The reduction in neuro-
trophic factors could trigger robust HSV replication, overwhelming
anti-viral immune surveillance. Alternatively, the local immune
response at the site of vaccination could distract normal
immunologic surveillance, such that the number of T cells
normally present near infected neurons was effectively decreased,
resulting in loss of immunologic control.
In our patient, there was a reproducible temporal relationship
between sequential inﬂuenza vaccinations and HSV reactivation.
He ﬁrst presented with encephalitis just days after vaccination. The
following year, he presented with similar, albeit milder symptoms.
While HSV was not detected in his CSF at the second presentation,
it may have represented transient viral reactivation. His ﬁnal
vaccination preceded HSV infection at a second neurologic site, the
retina.
Given the widespread safe and efﬁcacious use of inﬂuenza
vaccinations even in persons with signiﬁcant immune compro-
mise, there were likely multiple host and viral factors that
contributed to our patient’s disease. Our patient did not have a
recent history of orolabial herpetic infection, nor did he suffer from
frequent colds or other viral illnesses to suggest a generalized
immunologic deﬁciency. In fact, his immune studies demonstrated
normal humoral immunity. He does, however, appear to have 25–
75% fewer circulating CD4T cells than normal during these
episodes. This could translate to a relative paucity in immune
surveillance within the CNS. Indeed, impaired cellular immunity
has been previously reported in a subset of ARN patients [20]. A
subtle immunologic deﬁciency in our patient may have lowered
the threshold for clinically signiﬁcant HSV reactivation in the CNS.
Subsequently, vaccination may have drawn the T cells normally
involved in CNS immune surveillance toward the vaccine response,
allowing viral reactivation to proceed unchecked. Additionally,
vaccine-induced inﬂammatory cytokines may have triggered viral
reactivation directly, or indirectly via neurotoxicity or loss of
neurotrophic support.
The current inﬂuenza vaccines are extraordinarily safe and
efﬁcacious, even in patients with severe immune deﬁciencies and
pre-existing CNS disease, with the reported neurologic sequelae
existing at the level of case reports. This case divulges, not the
perils of inﬂuenza vaccination, but the complexity of the HSV-1-
host interface, and begs for greater understanding, and therapeutic
manipulation, of the forces that govern it.
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